MAH0 Stock Chart & Stats
€0.27
-€0.01(-0.29%)
At close: 4:00 PM EST
€0.27
-€0.01(-0.29%)
Day’s Range― - ―
52-Week Range€0.20 - €1.95
Previous CloseN/A
Volume0.00
Average Volume (3M)182.00
Market Cap
€42.75M
Enterprise Value€13.26M
Total Cash (Recent Filing)€36.22M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding159,618,600
10 Day Avg. Volume518
30 Day Avg. Volume182
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.62Price Target Upside871.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€12.53M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-free Balance SheetZero reported total debt provides durable financial flexibility: it reduces fixed interest obligations and preserves capacity to fund R&D or weather delays. Over a 2–6 month horizon this strengthens the company’s ability to pursue development milestones or seek non-debt financing without interest pressure.
Clinical-stage Pipeline & Partnership StrategyA focused antibody/protein portfolio targeting oncology and rare diseases plus an explicit collaboration strategy is structurally advantageous: it concentrates resources on high-value indications and allows the company to accelerate development or share costs through partnerships, improving chances of achieving commercial milestones.
Authorized Equity Issuance Extends Financing OptionsBoard authority to issue shares non-pre-emptively through 2029 is a durable governance tool that materially increases the company’s ability to raise capital when needed. This structural flexibility can extend runway for clinical programs and enable strategic partnerships or licensing without requiring debt financing.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flows indicate the company is consuming cash to fund operations and trials. Over the next several months this continuous burn will force reliance on external financing or partnerships, constraining strategic optionality and increasing execution risk if funds are delayed.
Minimal Revenue With Large Net LossesNear-zero recurring revenue combined with very large trailing losses points to no internal profit engine to fund development. This structural profitability gap means the company remains dependent on financing until product approvals or meaningful commercialization, elevating long-term dilution and execution risk.
Declining Equity Base And Dilution RiskMaterial declines in shareholders' equity over recent periods reflect cumulative losses and past financings. Coupled with board authority to issue shares, this structural decline raises the probability of further equity raises and dilution, which can erode existing investor value and limit long-term return potential.
Mereo Biopharma Group Plc News
MAH0 FAQ
What was Mereo Biopharma’s price range in the past 12 months?
Mereo Biopharma lowest stock price was €0.20 and its highest was €1.95 in the past 12 months.
What is Mereo Biopharma’s market cap?
Mereo Biopharma’s market cap is €42.75M.
When is Mereo Biopharma’s upcoming earnings report date?
Mereo Biopharma’s upcoming earnings report date is Aug 18, 2026 which is in 26 days.
How were Mereo Biopharma’s earnings last quarter?
Mereo Biopharma released its earnings results on May 12, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.008 by >-€0.001.
Is Mereo Biopharma overvalued?
According to Wall Street analysts Mereo Biopharma’s price is currently Undervalued.
Does Mereo Biopharma pay dividends?
Mereo Biopharma does not currently pay dividends.
What is Mereo Biopharma’s EPS estimate?
Mereo Biopharma’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma have?
Mereo Biopharma has 159,618,600 shares outstanding.
What happened to Mereo Biopharma’s price movement after its last earnings report?
Mereo Biopharma reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went down -2.913%.
Which hedge fund is a major shareholder of Mereo Biopharma?
Currently, no hedge funds are holding shares in DE:MAH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.55%
Trailing 12-Months
Company Description
Mereo Biopharma
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MAH0 Stock 12 Month Forecast
Average Price Target
€2.62
▲(871.23% Upside)